NCT03529084 2019-11-22
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Novartis
Phase 3 Withdrawn
Novartis
Barbara Ann Karmanos Cancer Institute
AstraZeneca
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center